A carregar...
Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology
IMPORTANCE: To date, the benefit of genome-driven cancer therapy has not been quantified. OBJECTIVE: We sought to estimate the annual percentage of patients in the United States with advanced or metastatic cancer who could be eligible for and benefit from US Food and Drug Administration (FDA)-approv...
Na minha lista:
| Publicado no: | JAMA Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Medical Association
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6143048/ https://ncbi.nlm.nih.gov/pubmed/29710180 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.1660 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|